"Selinexor–Dexamethasone Combo Induces Objective Responses in Refractory MM"
Selinexor therapy plus dexamethasone was active and induced objective responses in patients with multiple myeloma (MM) who are refractory to current treatment options, according to researchers at the Icahn School of Medicine at Mount Sinai and published in The New England Journal of Medicine. The primary end point of the study was overall response, defined as a partial response or greater, and was assessed by an independent review committee. A secondary end point was clinical benefit, defined as a minimal response or greater. According to lead author Ajai Chari, MD, director of clinical research in the Multiple Myeloma Program at The Tisch Cancer Institute at Mount Sinai, “Selinexor–dexamethasone resulted in objective treatment responses in patients with myeloma refractory to currently available therapies.”
— Ajai Chari, MD, Director, Clinical Research in the Multiple Myeloma Program, Associate Director, Clinical Research, Mount Sinai Cancer Clinical Trials Office, Associate Professor, Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai